Impact of the Spread of COVID-19 on Demand, Operations and Research and Development
First written in FY2020. 8 of 12 entries say "Mitigated", first in FY2021-Q2. Latest entry: FY2023-Q3.
The whole theme swung hardest in 2020: 103 of 175 companies on the "Worse" side.
- FY2023-Q3MitigatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, healthcare demand, which had declined due to the spread of COVID-19 in the previous fiscal year, recovered, and exchange rates also contributed, resulting in generally strong sales by the Group.」
The impact of COVID-19 on demand and operations was substantially alleviated, mainly overseas, as healthcare demand recovered. In Japan, however, the recovery in healthcare demand was delayed by the eighth wave. - FY2023-Q2MitigatedAnnual report
「Healthcare demand, which had declined in the previous fiscal year due to the spread of COVID-19, recovered, and foreign exchange movements also contributed, resulting in generally strong sales for the Group.」
Healthcare demand, which had declined due to the spread of COVID-19, recovered and sales were generally strong. In Japan, however, the recovery was delayed by the seventh wave. - FY2023-Q1MitigatedAnnual report
「Healthcare demand, which had declined due to the spread of COVID-19 in the previous fiscal year, recovered, and the Group's sales were generally strong.」
The impact of COVID-19 on demand and operations was substantially alleviated as healthcare demand recovered. Company-wide revenue increased 14.9% year on year, but profit declined due in part to the resumption of sales promotion activities that had been restrained before the spread of the infection. - FY2022MitigatedAnnual report
「The impact of the COVID-19 outbreak that began in the previous fiscal year was substantially alleviated, particularly in North America and Europe, and healthcare demand recovered as COVID-19 vaccines became more widely available, elective procedures that had been postponed across various medical specialties were performed, and tests, diagnoses and hospital admissions increased.」
The impact of COVID-19 on demand and operations was substantially alleviated, and company-wide revenue increased 14.6% year on year. Meanwhile, the cost impact of higher manufacturing and transportation costs remained. - FY2022-Q3MitigatedAnnual report
「During the cumulative third quarter of the current consolidated fiscal year, the recovery in healthcare demand from the impact of COVID-19 observed in the first quarter continued, and sales by the Group were generally strong.」
The impact of COVID-19 on demand and operations was alleviated to the point where healthcare demand continued to recover and sales were generally strong. Meanwhile, new issues, including supply chain disruptions, have emerged. - FY2022-Q2MitigatedAnnual report
「The impact of the COVID-19 outbreak that began in the previous fiscal year was substantially alleviated, particularly in North America and Europe, and healthcare demand recovered as COVID-19 vaccines became more widely available, elective procedures that had been postponed across various medical specialties were performed, and tests, diagnoses and hospital admissions increased.」
The impact of COVID-19 on demand and operations was substantially alleviated, particularly in North America and Europe, and company-wide revenue increased 21.7% year on year as healthcare demand recovered. - FY2022-Q1MitigatedAnnual report
「During the first quarter of the current consolidated cumulative period (1 April 2021 to 30 June 2021), the impact of the COVID-19 outbreak that began in the previous fiscal year was substantially alleviated in the medical market. Particularly in North America and Europe, as COVID-19 vaccines became more widely available, healthcare demand recovered through the performance of elective procedures that had been postponed across various medical specialties, as well as increases in tests, diagnoses and hospital admissions.」
The impact of COVID-19 on demand and operations was substantially alleviated, particularly in North America and Europe. Healthcare demand recovered as postponed cases, testing and diagnosis, and hospital admissions increased with the rollout of vaccines, and company-wide revenue increased 30.8% year on year. - FY2021WorsenedAnnual report
「The business is also expected to be affected by the spread of COVID-19 in fiscal 2021. Although it is difficult to accurately forecast the affected regions, period, and scale, the upper end of the earnings forecast assumes a scenario in which vaccine availability and the recovery in healthcare demand advance from the first half, allowing a return to the growth trajectory. The lower end assumes a scenario in which, as in fiscal 2020, the number of infections rises and falls in regions worldwide during the first half, with the spread of the disease finally brought under control and recovery beginning in the second half.」
The impact of COVID-19 remained in full-year FY2021 results, and the outlook for the fiscal year ending March 2022 was set using upper and lower scenarios with a range of possible recovery timing, regions, and scale. - FY2021-Q3Impact limited during the renewed spreadAnnual report
「The business was significantly affected by the spread of COVID-19, particularly in April and May, with lower demand across various medical specialties due to postponed elective cases, fewer tests and diagnoses, and shorter hospital stays. Demand recovered to a certain extent in July–September as some of the postponed cases were performed. Although a renewed spread of COVID-19 was seen in October–December, particularly in Europe and the Americas, its impact on healthcare providers’ operations was limited.」
Describes the progression from lower demand in April–May, to a certain degree of recovery in July–September, and then to the renewed spread in Europe and the Americas in October–December, with limited impact on healthcare providers. - FY2021-Q2MitigatedAnnual report
「Demand recovered to a certain extent in July–September as some of the postponed cases were performed.」
The decline in demand due to COVID-19 continued, with cumulative revenue down 7.8% year on year and the Cardiovascular Company down 13.4%. Meanwhile, demand recovered to a certain extent in July–September as some postponed cases were performed, with a particularly notable recovery in the cardiovascular field overseas. - FY2021-Q1WorsenedAnnual report
「The business was significantly affected by the spread of the novel coronavirus, particularly in April and May, with lower demand across various medical specialties due to postponed elective cases, fewer tests and diagnoses, and shorter hospital stays.」
The impact of the spread of the novel coronavirus on demand and operations expanded and became more pronounced in FY2021-Q1. Revenue decreased 13.9% year on year, adjusted operating profit decreased 36.1%, and the Cardiovascular Company decreased 23.9%. - FY2020MaterialisedAnnual report
「The Company expects to be affected by the spread of COVID-19 during FY2020. In addition to a temporary decline in demand, attention should also be paid to lower production operating rates and delays in research and development.」
Disclosed the spread of the novel coronavirus as a new significant risk leading to lower demand, lower production utilization, delays in research and development, and postponement of cases in the cardiovascular field. A slowdown in the China TIS business and other factors occurred in the fourth quarter, with the impact on adjusted operating profit quantified at ¥2.7 billion.